DENVER, CO / ACCESSWIRE / October 7, 2024 / SOBR Safe, Inc. (NASDAQ:SOBR) ("SOBRsafe"), provider of next-generation transdermal alcohol detection solutions, today announced the pricing of a private placement with certain institutional investors. The aggregate gross cash proceeds are expected to be $8.2 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital.
In connection with the private placement, the Company is planning to issue an aggregate of 2,024,691 units. Each unit will be sold at an effective unit price of $4.05 per unit and will consist of one share of common stock (or one pre-funded warrant in lieu thereof), two (2) Series A warrants, each exercisable for one share of common stock at an initial exercise price of $3.80 per share and one Series B warrant at an exercise price of $0.001 to purchase such number of shares of common stock as will be determined on the Reset Date (as defined in the Series B warrant). The Series A warrants and the Series B warrants are exercisable beginning on the date that Stockholder Approval (as defined in the Series A warrant) is obtained. The Series A warrants will have a term of 5 years and the Series B warrants are exercisable until exercised in full. The exercise price and number of shares of common stock issuable upon exercise of the Series A warrants are subject to adjustment upon future dilutive issuances and stock splits, subject to a floor, and the exercise price and number of shares of common stock issuable upon exercise of the Series B warrants are subject to adjustment upon stock splits, subject to a floor, in each case, as described in more detail in the Current Report on Form 8-K to be filed in connection with the private placement.
The closing of the private placement is expected to occur on or about October 8, 2024, subject to the satisfaction of certain customary closing conditions.
Aegis Capital Corp. is acting as the Exclusive Placement Agent for the private placement. Lucosky Brookman LLP is acting as counsel to the Company. Sichenzia Ross Ference Carmel LLP is acting as counsel to Aegis Capital Corp.
The securities described above are being sold in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "Act"), and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the "SEC") covering the resale of the common stock sold in the private placement and the common stock issuable upon exercise of the pre-funded warrants and the warrants sold in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.---
About SOBRsafe
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way.
Enter SOBRsafe. Our advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user's skin - no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration.
The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). At SOBRsafe, our mission is to create better outcomes and save lives.
丹佛,科罗拉多州/ACCESSWIRE/2024年10月7日/SOBR Safe,Inc.(纳斯达克: SOBR)("SOBRsafe"),提供下一代透皮酒精检测解决方案的服务提供商,今日宣布与某些机构投资者达成定向增发的定价。预计总募集资金将达到820万美元,扣除支付给放置代理商和公司支付的其他发行费用之前。公司计划将定向增发的净收益用于一般企业用途和营运资金。
为了配合定向增发,公司计划发行总计2,024,691单位。每单位售价为$4.05,其中包括一股普通股(或一股预先担保的认股权证),两(2)个A系列认股权证,每个认股权证以初始行使价格$3.80每股行使,以及一项B系列认股权证,行使价格为$0.001,以购买将在重置日期(B系列认股权证中定义的日期)确定的普通股数量。A系列认股权证和B系列认股权证的行使期始于取得股东批准(A系列认股权证中定义的批准)的日期。A系列认股权证期限为5年,B系列认股权证可行使直至完全行使。A系列认股权证的行使价格和行使日期取得未来稀释性发行和股票拆股并股的调整,受限于底线,B系列认股权证的行使价格和行使日期也会受到股票拆股并股的调整的影响,同样受限于底线,具体情况请参阅与定向增发有关的8-k表格中更详细的说明。
预计定向增发交易将于2024年10月8日左右完成,前提是满足某些常规的交易结束条件。
Aegis Capital Corp.担任定向增发的独家代理商。Lucosky Brookman LLP担任公司的法律顾问。Sichenzia Ross Ference Carmel LLP担任Aegis Capital Corp的法律顾问。
上述证券是根据1933年修订版证券法案("法案")规定的豁免权进行的私下配售,并未在该法案或适用州证券法案下注册。因此,除非根据生效的注册声明或适用的法案注册要求免除的情况下,这些证券可能不会在美国境内提供或出售,也可能未在任何州或司法管辖区内提供或出售。根据与投资者达成的注册权协议,公司已同意向美国证券交易委员会("SEC")提交一个或多个注册声明,涵盖私下配售所售普通股及预融资认股权证和定向增发中出售的认股权证的再销售。
此新闻稿不构成出售或购买本处所述证券的要约,也不构成在任何该类出售未经任何州或司法管辖区证券法律注册或符合资格前违法的要约、征求或出售。---
关于SOBRsafe
酒精滥用是美国第四大可预防死因,全球排名第七。然而,预防和监测解决方案没有跟上这一流行病的步伐。遗留的技术具有侵入性、效率低下、不卫生、不连通的特点。必须有更好的解决方案。
SOBRsafe即应运而生。我们先进的经皮(触摸)技术能够检测并即时报告用户通过皮肤散发出的酒精浓度——无需呼气、血液或尿液检测。通过强大的后端数据平台,SOBRsafe为行为健康、司法和消费市场提供下一代被动式检测技术,以及用于许可和集成的技术。
SOBRsafe技术已商业化,可用于现场筛查(SOBRcheck)和持续监测(SOBRsure)。在SOBRsafe,我们的使命是创造更好的结果并拯救生命。